Literature DB >> 20979968

Racial differences in chronic kidney disease (CKD) and end-stage renal disease (ESRD) in the United States: a social and economic dilemma.

T Palmer Alves1, J Lewis.   

Abstract

Chronic kidney disease (CKD), defined as an eGFR < 60 ml/min/1.73 m², affects up to 25% of the United States population. In addition, it is estimated that approximately 6% of the population have early evidence of CKD and will likely progress to end stage renal disease (ESRD) in the near future. Further, ESRD is more common in many ethnic minorities, with African-Americans having the highest rates of treated ESRD, closely followed by Hispanic Americans, when compared to non- Hispanic White persons. Although African-Americans with CKD are more likely to die than non-Hispanic White persons with CKD, these trends reverse once progression to ESRD is established. The reasons for the disparities in the prevalence and incidence of CKD, ESRD, and mortality are unclear, but likely involve a complex interaction of socioeconomic, environmental and genetic factors. This review highlights current data pertaining to the social and economic impact of ethnic differences in the prevalence and incidence of CKD and ESRD in the United Stated. It is hoped that highlighting the current trend of kidney related health disparities will not only lead to an improved understanding of these issues, but also more informed research agendas, that are ultimately aimed at alleviating ethnic differences in kidney health outcomes.

Entities:  

Mesh:

Year:  2010        PMID: 20979968     DOI: 10.5414/cnp74s072

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  28 in total

1.  Serum calcium and its complex association with incident type 2 diabetes.

Authors:  Ranee Chatterjee; Pao-Hwa Lin
Journal:  Am J Clin Nutr       Date:  2016-09-14       Impact factor: 7.045

2.  Osmoregulatory defect in adult mice associated with deficient prenatal expression of six2.

Authors:  S Jack Somponpun; Brittany Wong; Thomas E Hynd; Benjamin Fogelgren; Scott Lozanoff
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-06-08       Impact factor: 3.619

3.  The safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluation.

Authors:  Rami Doukky; Maria Octavia Rangel; Marwan Wassouf; Rizcallah Dick; Ammar Alqaid; Raysa Morales Demori
Journal:  J Nucl Cardiol       Date:  2012-12-13       Impact factor: 5.952

4.  Variability in CKD stage in outpatients followed in two large renal clinics.

Authors:  Tabo Sikaneta; Mohamed Abdolell; Hulya Taskapan; Janet Roscoe; Jason Fung; Gordon Nagai; Robert H Ting; Paul Ng; George Wu; Dimitrios Oreopoulos; Paul Y Tam
Journal:  Int Urol Nephrol       Date:  2011-03-20       Impact factor: 2.370

5.  Racial disparities in pediatric access to kidney transplantation: does socioeconomic status play a role?

Authors:  R E Patzer; S Amaral; M Klein; N Kutner; J P Perryman; J A Gazmararian; W M McClellan
Journal:  Am J Transplant       Date:  2012-01-06       Impact factor: 8.086

6.  Attenuation of the side effect profile of regadenoson: a randomized double-blind placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging and have severe chronic kidney disease--the ASSUAGE-CKD trial.

Authors:  Rami Doukky; Maria Octavia Rangel; Rizcallah Dick; Marwan Wassouf; Ammar Alqaid; Bosko Margeta
Journal:  Int J Cardiovasc Imaging       Date:  2012-12-11       Impact factor: 2.357

7.  Impact of renal function on treatment options and outcomes in advanced non-small cell lung cancer.

Authors:  Bercin Kutluk Cenik; Han Sun; David E Gerber
Journal:  Lung Cancer       Date:  2013-03-15       Impact factor: 5.705

8.  Adherence to hemodialysis dietary sodium recommendations: influence of patient characteristics, self-efficacy, and perceived barriers.

Authors:  Maya N Clark-Cutaia; Dianxu Ren; Leslie A Hoffman; Lora E Burke; Mary Ann Sevick
Journal:  J Ren Nutr       Date:  2014-01-24       Impact factor: 3.655

9.  Achieving Equity in an Evolving Healthcare System: Opportunities and Challenges.

Authors:  Joni Strom Williams; Rebekah J Walker; Leonard E Egede
Journal:  Am J Med Sci       Date:  2016-01       Impact factor: 2.378

10.  ets1 associates with KMT5A to participate in high glucose-mediated EndMT via upregulation of PFN2 expression in diabetic nephropathy.

Authors:  Lihong Lu; Ziwen Zhong; Jiahui Gu; Ke Nan; Minmin Zhu; Changhong Miao
Journal:  Mol Med       Date:  2021-07-08       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.